Stay updated with breaking news from Priority Review. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer Inc on Tuesday said that the US Food & Drug Administration has agreed to review its licence application to get full approval for Tivdak in patients with recurrent or metastatic cervical...
FDA’s Center for Drug Evaluation and Research (CDER) approved a wide range of therapies in 2023 that will help patients and consumers live better and possibly longer lives.
Pfizer and Genmab are seeking full approval for Tivdak® (tisotumab vedotin-tftv) in patients with recurrent or metastatic cervical cancer.
The post-hoc analysis of the phase 3 ENHANCE study provides the first published evidence of a correlation between decreases in IL-31, bile acids, and pruritus symptoms in PBC following treatment with an investigational agent.
JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) of China